DOI: 10.25881/BPNMSC.2019.69.94.029


Pacenko M.B.1, Tyurin V.P.2, Platov S.Е.1, Brovko L.Е.1, Stojka B.M.1

1 FBU “3 Central military clinical hospital. AA Vishnevsky,” Russian defense Ministry, Krasnogorsk

2 Federal State Public Institution «National Medical and Surgical Center named after N.I. Pirogov» of the Ministry of Healthcare of the Russian Federation


A clinical case of successful treatment of infectious endocarditis caused by methicillin-resistant epidermal Staphylococcus (MRSE) with ceftarolin fosamil, a representative of the 5th generation of cephalosporins, is presented. Against the background of comorbidity in the form of coronary heart disease, stenting of the anterior interventricular artery and non-alcoholic cirrhosis of the liver, a cure was achieved without progression of concomitant diseases.

Keywords: infective endocarditis, ceftarolin fosamil, MRSE, echocardiography.


1. Danilov AI. Razrabotka podkhodov k optimizatsii antimikrobnoi terapii infektsionnogo endokardita na osnove analiza real’noi praktiki vedeniya patsientov v Rossiiskoi Federatsii. [dissertation abstract] Moscow; 2018. 24 p. (In Russ).

2. Arshad S, Huang V, Hartman P, Perri MB, Moreno D, Zervos MJ. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study. Int J Infect Dis. 2017;57:27-31. doi: 10.1016/j.ijid.2017.01.019.

3. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, Barsic B, Lockhart PB, Gewitz MH, Levison ME, Bolger AF, Steckelberg JM, Baltimore RS, Fink AM, O’Gara P, Taubert KA; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a Scientific Statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435-1486. doi: 10.1161/CIR.0000000000000296.

4. Baxi SM, Chan D, Jain V. Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature. Infection. 2015;43(6):751–754. doi: 10.1007/s15010-015-0763-0.

5. Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, Pogue JM, Rybak MJ. Large retrospective evalution of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014; 58(5):2541–2546. doi: 10.1128/AAC.02371-13.

6. Nigo M, Diaz L, Carvajal LP, Tran TT, Rios R, Panesso D, Garavito JD, Miller WR, Wanger A, Weinstock G, Munita JM, Arias CA, Chambers HF. Ceftaroline-resistant, daptomycin-tolerant, and heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus causing infective endocarditis. Antimicrob Agents Chemother. 2017; 61(3):e01235-16. doi: 10.1128/AAC.01235-16.

7. Dohmen PM, Guleri A, Capone A, Utili R, Seaton RA, González-Ramallo VJ, Pathan R, Heep M, Chaves RL. Daptomycin for the treatment of infective endocarditis: results from a European registry. J Antimicrob Chemother. 2013;68(4):936–942. doi: 10.1093/jac/dks467.

8. Fabre V, Ferrada M, Buckel WR, Avdic E, Cosgrove SE. Ceftaroline in combination with trimethoprim-sulfamethoxazole for salvage therapy of methicillin-resistant Staphylococcus aureus bacteriemia and endocarditis. Open Forum Infect Dis. 2014;1(2):ofu046. doi: 10.1093/ofid/ofu046.

9. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska-Gosciniak E, Price S, Roos-Hesselink J, Snygg-Martin U, Thuny F, Tornos Mas P, Vilacosta I, Zamorano JL; ESC Scientific Document Group. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075–3128. doi: 10.1093/eurheartj/ehv319.

10. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS 2nd. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67(5):1267–1270. doi: 10.1093/jac/dks006.

11. Jongsma K, Joson J, Heidari A. Ceftarolinee treatment of concomitant methicillin-resistant qand daptomycin-non-susceptible Staphylococcus aureus infective endocarditis and osteomyelitis: case report. J Antimicrob Chemother. 2013;68(6):1444–1445. doi: 10.1093/jac/dkt009.

12. Destache CJ, Guervil DJ, Kaye KS. Gram-positive infective endocarditis treated with Ceftaroline fosamil: CAPTURE study experience.Int J Antimicrob Agents. 2019;53(5): 644–649. doi: 10.1016/j.ijantimicag.2019.01.014.

13. Lin JC, Aung G, Thomas A, Jahng M, Johns S, Fierer J. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother. 2013;19(1):42–49. doi: 10.1007/s10156-012-0449-9.

14. Sader HS, Flamm RK, Jones RN. Tygecicline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide. Diagn Microbiol Infect Dis. 2013;76(2):217–221. doi: 10.1016/j.diagmicrobio.2013.02.009.

15. Sakoulas G, Nonejuie P, Nizet V, Pogliano J, Crum-Cianflone N, Haddad F. Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline. Antimicrob Agents Chemother. 2013;57(8):4042–4045. doi: 10.1128/AAC.02481-12.

16. Scott LJ, Frampton JE. Ceftaroline fosamil: a guide to its use in complicated skin and soft tissue infections and community-acquired pneumonia in the EU. Drugs Ther Perspect. 2015;31:9–16. doi: 10.1007/s40267-014-0174-9.

17. Sundaragiri PR, Vallabhajosyula S, Haddad TM, Esterbrooks DJ. Tricuspid and mitral emdocarditis due to methicillin-resistant Staphylococcus aureus exhibiting vancomycin-creep phenomenon. BMJ Case Rep. 2015;2015:bcr2015211974. doi: 10.1136/bcr-2015-211974.

18. Tattevin P, Boutoille D, Vitrat V, Van Grunderbeeck N, Revest M, Dupont M, Alfandari S, Stahl JP. Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study. J Antimicrob Chemother. 2014;69(7):2010–2013. doi: 10.1093/jac/dku085.

19. Zasowski EJ, Trinh TD, Claeys KC, Casapao AM, Sabagha N, Lagnf AM, Klinker KP, Davis SL, Rybak MJ. Multicenter observational study of Ceftaroline fosamil for methicillin-resistant Staphilcoccus aureus bloodstream infections. Antimicrob Agents Chemother. 2017;61(2):e02015-16. doi: 10.1128/AAC.02015-16.

For citation

Pacenko M.B., Tyurin V.P., Platov S.Е., Brovko L.Е., Stojka B.M. Ceftaroline fosamil in the treatment of staphylococcal infective endocarditis. Bulletin of Pirogov National Medical & Surgical Center. 2019;2(14):135-137. (In Russ.)